Business Context and Reporting Period
Company: Cardinal Health, Inc. (formerly Cardinal Distribution, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 31, 1994 (Fiscal Year 1995).
Business Overview: The Company operates as a wholesale drug distributor. The reporting period reflects significant growth driven by internal expansion and strategic acquisitions, including Humiston-Keeling, Inc. (purchase method) and Behrens Inc. (pooling-of-interests). Financial statements have been retroactively adjusted to reflect the February 1994 pooling-of-interests merger with Whitmire Distribution Corporation.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 1994 | Six Months Ended Dec 31, 1993 | Three Months Ended Dec 31, 1994 |
|---|---|---|---|
| Net Sales | $3,804,550 | $2,689,239 | $1,985,863 |
| Gross Margin | $215,832 (5.67%) | $161,087 (5.99%) | $112,475 (5.66%) |
| Operating Earnings | $69,831 | $52,676 | $38,675 |
| Net Earnings | $36,902 | $27,419 | $20,877 |
| Earnings Per Share (Diluted) | $0.88 | $0.67 | $0.49 |
| Cash and Equivalents (End of Period) | $53,632 | $71,756 | $53,632 |
| Net Working Capital | $561,800 | $471,100 (June 30, 1994) | N/A |
| Total Debt (Short + Long Term) | $290,096 | N/A | N/A |
Note: All figures in thousands except per share data. Debt includes $77.8M notes payable, $3.5M current portion of long-term obligations, and $209.8M long-term obligations.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 41% for the six-month period and 42% for the quarter compared to the prior year. This was driven by 31% internal growth (new and existing customers) and contributions from acquisitions.
- Margin Compression: Gross margin percentage declined to 5.67% (six months) from 5.99% in the prior year. Management attributes this to lower selling margin rates due to a more competitive market and a higher mix of volume customers.
- Expense Efficiency: Selling, general, and administrative (SG&A) expenses improved as a percentage of sales to 3.84% (six months) from 4.03% in the prior year, aided by economies of scale and distribution center consolidation.
- Cash Flow: Net cash used in operating activities was $60.4 million, compared to $21.9 million used in the prior year. This increase was primarily due to significant investments in trade receivables ($120.4M increase) and merchandise inventories ($204.8M increase) to support growth and acquisitions.
- Capital Structure: Shareholders' equity increased to $500.4 million from $368.5 million at the prior fiscal year-end, driven by a public offering of common shares (net proceeds ~$70M), net earnings, and tax benefits from stock option exercises.
Guidance, Outlook, and Risks
- Outlook: Management expects the decline in gross margin rates to continue but at a more moderate pace. The Company believes it has adequate resources to meet capital expenditures, business growth, and debt service requirements.
- Liquidity: The Company maintains $310 million in line-of-credit arrangements ($100M committed), with $77.8 million outstanding as of December 31, 1994. A registration statement for an additional $150 million of debt securities was filed in January 1995 but was not yet effective as of January 27, 1995.
- Legal Contingencies: The Company is a defendant in consolidated class action antitrust lawsuits ("Brand Name Prescription Drug Litigation") alleging conspiracy to inflate prices. A Judgment Sharing Agreement limits the Company's exposure to the lesser of 1% of any judgment or $1 million, with manufacturers agreeing to reimburse litigation costs up to $9 million. Plaintiffs have challenged the enforceability of this agreement; the Company intends to contest the allegations vigorously.
- Acquisitions: Recent acquisitions of Humiston-Keeling and Behrens are expected to contribute to future growth, though the Behrens combination was deemed not significant enough to restate prior periods.
Investor Verification Checklist
- Margin Sustainability: Verify if the trend of declining gross margins (5.66% - 5.67%) stabilizes in future quarters as management predicts.
- Working Capital Efficiency: Monitor the ratio of inventory and receivables growth relative to sales growth to ensure cash flow does not remain negative due to asset buildup.
- Legal Exposure: Track the court ruling on the enforceability of the Judgment Sharing Agreement in the antitrust litigation to confirm the $1 million liability cap remains valid.
- Debt Capacity: Confirm the effectiveness of the new $150 million debt registration statement filed in January 1995 to assess future refinancing capabilities.
- Acquisition Integration: Assess the financial performance of Humiston-Keeling and Behrens in subsequent reports to validate the pro forma assumptions made at the time of acquisition.